Life Sciences

  • February 10, 2026

    Lutnick Rules Out Creating Value-Based Fees For Patents

    Commerce Secretary Howard Lutnick told a Senate panel Tuesday that the government is not planning to establish new fees for U.S. patents based on their value, saying the idea he was reportedly considering "is not going anywhere."

  • February 10, 2026

    Lipid Testing Patents Recite Laws Of Nature, Judge Says

    A Massachusetts federal judge has dismissed a company's infringement claims against a rival over patents that cover methods of testing for lysosomal storage disorders, ruling that the patents only cited patent-ineligible laws of nature.

  • February 10, 2026

    Apple Again Pushes To Escape Masimo's $634M IP Verdict

    Apple is doubling down on its bid to have U.S. District Judge James V. Selna relieve it from a jury's $634 million infringement verdict in litigation over its Apple Watch, saying Masimo Corp. relied on an improper and "shifting" definition of a dispositive term.

  • February 10, 2026

    Pa. Hospital Settles Ex-Worker's ADA Suit Over CBD Gummy

    UPMC Pinnacle Hospitals has settled a former employee's disability discrimination suit claiming he was unlawfully fired when he tested positive for cannabis because he took cannabidiol gummies used to treat his spinal condition.

  • February 10, 2026

    Judge Questions Timing Of Case Against Harvard Researcher

    A Massachusetts federal judge on Tuesday ordered the U.S. Attorney's Office to turn over materials related to its decision to prosecute a Harvard Medical School researcher and Russian national found with inert frog embryo specimens last year at Logan Airport, calling the timing of the case "a red flag."

  • February 10, 2026

    Astellas Gets $90M From Lupin In Myrbetriq Patent Deal

    Generic-drug maker Lupin Pharmaceuticals has inked a deal to pay $90 million to settle claims that it infringed patents held by rival Astellas Pharma Inc. covering name-brand bladder drug Myrbetriq.

  • February 10, 2026

    Norton Rose Hires Cooley Life Sciences Duo In DC

    Norton Rose Fulbright has hired two life sciences attorneys from Cooley LLP in Washington, D.C., who focus on biotech and pharmaceutical intellectual property matters, in a move the firm said is an investment in IP as a core practice.

  • February 10, 2026

    Whooping Cough-Focused Biotech Wraps $115M Fundraise

    Florida-based biotechnology company ILiAD Biotechnologies Inc. on Tuesday revealed that it wrapped its latest financing round after securing $115 million from investors, which will be used to advance development on a potential whooping cough vaccine.

  • February 09, 2026

    Kurin Fights $1.6M IP Verdict As Rival Seeks More Damages

    Kurin has urged a Delaware federal judge to overturn Magnolia Medical's $1.6 million patent verdict or order a new trial, while Magnolia Medical has asked the court to bar Kurin from selling allegedly infringing "Jet" blood-culture collection products and award it supplemental damages on Kurin's sales, plus ongoing royalties and interest.

  • February 09, 2026

    Defendant Mix-Up Ends Biotech FCA Suit, For Now

    A New York federal court ruled that a relator's False Claims Act suit failed to link claims of improper COVID-19 billing and other alleged schemes to defraud Medicare to the biotech company it named as a defendant, dismissing the complaint with leave to amend.

  • February 09, 2026

    Italian Biathlete Lodges Appeal Of Olympic Doping Ban

    Italian biathlete Rebecca Passler, who was booted from the Olympic team last week after a positive doping test, has appealed the decision to the Court of Arbitration for Sport, asserting that the test result arose from a contamination issue.

  • February 09, 2026

    Fed. Circ. Sends Blood Pump Patent Fight Back To Mass.

    The Federal Circuit on Monday reversed a lower court's ruling that Abiomed Inc. hasn't infringed five patents on blood pump systems and methods, while backing the part of the decision that cleared the medical device technology company of allegations it infringed a different patent.

  • February 09, 2026

    Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1

    Novo Nordisk AS followed through on Monday in Delaware federal court on a plan it announced last week to sue telehealth company Hims & Hers Health Inc. over its marketing of what Novo Nordisk calls a knockoff version of its GLP-1 medications.

  • February 09, 2026

    High Court Asked To Take Up Malpractice Case Against Akin

    A former Cornell University graduate student wants the U.S. Supreme Court to review the dismissal of his suit accusing Akin Gump Strauss Hauer & Feld LLP attorneys of manipulating patent litigation to steal his DNA sequencing intellectual property.

  • February 09, 2026

    Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy

    Pharmaceutical giant Eli Lilly & Co., advised by Paul Weiss Rifkind Wharton & Garrison LLP, on Monday announced that it has agreed to buy Goodwin Procter LLP-led biotechnology firm Orna Therapeutics Inc. in a deal where Orna shareholders could receive up to $2.4 billion in cash.

  • February 06, 2026

    Takeda Can't Ax Most Of Heartburn Drug Pay-For-Delay Suit

    Takeda Pharmaceutical Co. and TWi Pharmaceuticals must face most of a proposed antitrust class action accusing them of delaying the release of the generic version of Takeda's heartburn medication Dexilant, causing Walgreens, Kroger and other retailers to pay more for the brand-name drug, a California federal judge ruled Friday.

  • February 06, 2026

    Ga. Panel Backs Sperm Bank Win In 'Wrongful Birth' Case

    A Georgia appeals court backed a win for sperm bank Xytex Corp. in consolidated litigation alleging the company sold sperm under false pretenses about the medical, psychological and social history of the donors.

  • February 06, 2026

    HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight

    U.S. Department of Health and Human Services general counsel Mike Stuart announced Friday that his office referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation, a day after Novo Nordisk A/S threatened litigation over what it called the telehealth company's "knockoff" version of its popular weight loss drug Wegovy.

  • February 06, 2026

    NJ Judge Tosses Pacira Investor Suit Over Patent Loss

    A New Jersey federal judge on Friday threw out an investor lawsuit against Pacira BioSciences Inc. after a court invalidated a patent for its key pain management drug, ruling that the pharmaceutical company was not required to disclose litigation setbacks it encountered before the final ruling.

  • February 06, 2026

    Arizona Abortion Restrictions Found Unconstitutional

    An Arizona state court permanently struck down a slew of restrictions on abortion care in the state, including an ultrasound mandate and a ban on the mailing of abortion pills, finding that the restrictions violate the right to abortion enshrined in the state's constitution.

  • February 06, 2026

    PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test

    The Patent Trial and Appeal Board has found that Geneoscopy had shown that all the claims it challenged in a patent on Exact Sciences' colon cancer test Cologuard are invalid as obvious, months after the PTAB invalidated claims in a similar patent.

  • February 06, 2026

    3rd Circ. Remands J&J Unit's Libel Suit Over Talc Study

    Johnson & Johnson's talc liability unit will get another chance to pursue libel claims against a scientist over an article she wrote linking talcum power to mesothelioma, after the Third Circuit agreed to send the case back to New Jersey federal court. 

  • February 06, 2026

    TPG Hid Exactech Defects To Dodge Liability, Trust Alleges

    The settlement trust of joint implant maker Exactech filed a billion-dollar lawsuit in Delaware Chancery Court against TPG Inc., accusing the private equity firm of controlling Exactech after buying it in 2018, concealing the implants' defects, delaying product recalls and pushing the company into Chapter 11 to avoid liability.

  • February 06, 2026

    SEC Alleges Pharma Co. Misled Investors About Cancer Drug

    The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status of its cancer treatment drug.

  • February 06, 2026

    Beasley Allen Disqualified From NJ Talc Multicounty Litigation

    A New Jersey state appeals court disqualified the Beasley Allen Law Firm from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, ruling Friday that a former Faegre Drinker Biddle & Reath LLP lawyer's collaborative efforts with the firm's attorneys violated ethics rules.

Expert Analysis

  • 9th Circ. Ruling May Help Pharma Cos. Avert Investor Claims

    Author Photo

    The Ninth Circuit's recent decision affirming the dismissal of a securities fraud class action alleging that Talphera deceived investors by marketing a drug with a misleading slogan should give plaintiffs pause before filing similar complaints where snappy slogans are accompanied by copious clarifying information, say attorneys at Simpson Thacher.

  • What Ethics Rules Say On Atty Discipline For Online Speech

    Author Photo

    Though law firms are free to discipline employees for their online commentary about Charlie Kirk or other social media activity, saying crude or insensitive things on the internet generally doesn’t subject attorneys to professional discipline under the Model Rules of Professional Conduct, says Stacie H. Rosenzweig at Halling & Cayo.

  • Junior Attys Must Beware Of 5 Common Legal Brief Mistakes

    Excerpt from Practical Guidance
    Author Photo

    Junior law firm associates must be careful to avoid five common pitfalls when drafting legal briefs — from including every possible argument to not developing a theme — to build the reputation of a sought-after litigator, says James Argionis at Cozen O'Connor.

  • Opinion

    State AGs, Not Local Officials, Should Lead Public Litigation

    Author Photo

    Local governments’ public nuisance lawsuits can raise constitutional and jurisdictional challenges, reinforcing the principle that state attorneys general — not municipalities — are best positioned to litigate on behalf of citizens when it is warranted, says former Utah Attorney General John Swallow.

  • 3rd Circ. Clarifies Ch. 11 3rd-Party Liability Scope Post-Purdue

    Author Photo

    A recent Third Circuit decision that tort claims against the purchaser of a debtor's business belong to the debtor's bankruptcy estate reinvigorates the use of Chapter 11 for the resolution of nondebtor liability in mass tort bankruptcies following last year's U.S. Supreme Court ruling in Purdue Pharma, say attorneys at Sullivan & Cromwell.

  • Texas Suit Marks Renewed Focus On Service Kickback Theory

    Author Photo

    After a dormant period at the federal level, a theory of kickback enforcement surrounding nurse educator programs and patient support services resurfaced with a recent state court complaint filed by Texas against Eli Lilly, highlighting for drugmakers the ever-changing nature of enforcement priorities and industry landscapes, say attorneys at Sheppard Mullin.

  • Series

    Power To The Paralegals: How And Why Training Must Evolve

    Author Photo

    Empowering paralegals through new models of education that emphasize digital fluency, interdisciplinary collaboration and human-centered lawyering could help solve workforce challenges and the justice gap — if firms, educators and policymakers get on board, say Kristine Custodio Suero and Kelli Radnothy.

  • Series

    Playing Softball Makes Me A Better Lawyer

    Author Photo

    My time on the softball field has taught me lessons that also apply to success in legal work — on effective preparation, flexibility, communication and teamwork, says Sarah Abrams at Baleen Specialty.

  • 5 Years In, COVID-19 Fraud Enforcement Landscape Is Shifting

    Author Photo

    As the government moves pandemic fraud enforcement from small-dollar individual prosecutions to high-value corporate cases, and billions of dollars remain unaccounted for, companies and defense attorneys must take steps now to prepare for the next five years of scrutiny, says attorney David Tarras.

  • Fed. Circ. In August: A Framework For AIA Derivation Disputes

    Author Photo

    In Global Health Solutions v. Selner, the Federal Circuit established how to assess derivation challenges under the America Invents Act's first-to-file system, making it easier for petitioners to determine a challenge's odds of success, say attorneys at Knobbe Martens.

  • USPTO's Track One A Reliable Patent Pathway Amid Backlog

    Author Photo

    As the U.S. Patent and Trademark Office faces a backlog of unexamined utility, plant and reissue patent applications, patent applicants should consider utilizing the USPTO's Track One Program, which not only expedites the process but also increases the likelihood of working with more senior examiners, says Ryan Schermerhorn at Marshall Gerstein.

  • Vanda Ruling Opens Door For Contesting FDA Drug Denials

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.

  • Series

    Law School's Missed Lessons: Mastering Time Management

    Author Photo

    Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.

  • Rare Del. Oversight Ruling Sends Governance Wake-Up Call

    Author Photo

    An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.

  • How Hyperlinks Are Changing E-Discovery Responsibilities

    Author Photo

    A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.